Amexdrug Corporation
AXRX
$0.0021
$0.00015.00%
| 06/30/2013 | 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | |
|---|---|---|---|---|---|
| Revenue | 9.17M | 9.33M | 9.15M | 9.51M | 10.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.17M | 9.33M | 9.15M | 9.51M | 10.44M |
| Cost of Revenue | 7.91M | 8.17M | 8.15M | 8.74M | 9.58M |
| Gross Profit | 1.26M | 1.16M | 1.00M | 771.40K | 859.60K |
| SG&A Expenses | 880.40K | 841.30K | 786.90K | 800.80K | 808.10K |
| Depreciation & Amortization | 50.00K | 34.80K | 19.60K | 10.10K | 9.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.84M | 9.04M | 8.95M | 9.55M | 10.40M |
| Operating Income | 331.00K | 284.40K | 195.80K | -39.30K | 42.30K |
| Income Before Tax | 286.00K | 244.30K | 159.60K | -64.80K | 15.90K |
| Income Tax Expenses | 120.20K | 94.00K | 77.60K | -29.50K | 4.50K |
| Earnings from Continuing Operations | 0.17 | 0.15 | 0.08 | -0.04 | 0.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 165.90K | 150.30K | 82.10K | -35.20K | 11.40K |
| EBIT | 331.00K | 284.40K | 195.80K | -39.30K | 42.30K |
| EBITDA | 380.80K | 319.00K | 215.30K | -29.40K | 51.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 677.64M | 677.64M | 677.64M | 677.64M | 677.64M |
| Average Diluted Shares Outstanding | 677.64M | 677.64M | 677.64M | 677.64M | 677.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
